Introduction: Earlier reports described the possibility of higher SARS-CoV-2 infection and severity in patients with hematological malignancies. Given the importance and incidence of these malignancies, we aimed to systematically review SARS-CoV-2 infection and severity in patients with hematologic cancers.
Methods: We retrieved the relevant records by searching the keywords in online databases of PubMed, Web of Science, Cochrane, and Scopus on December 31st, 2021. A two-step screening; title/abstract and full-text screening, was employed to select the eligible studies. These eligible studies entered the final qualitative analysis. The study is adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist to ensure the reliability and validity of the results.
Results: Forty studies concerning different hematologic malignancies and the effect of COVID-19 infection on them were included in the final analysis. The findings showed that in general, the prevalence of SARS-CoV-2 infection and the severity of the disease are often higher in hematologic malignancies and the patients could experience higher morbidity and mortality compared to general populations.
Conclusion: It appeared that individuals with hematologic malignancies are more vulnerable to COVID-19 infection and they experience more severe disease with higher mortality rates. The presence of other comorbidities could also deteriorate this situation. Further investigation is recommended to evaluate the outcome of COVID-19 infection in different subtypes of hematologic malignancies.
早期的报告描述了血液系统恶性肿瘤患者中更高的SARS-CoV-2感染和严重程度的可能性。鉴于这些恶性肿瘤的重要性和发病率,我们旨在系统地回顾血液病患者的SARS-CoV-2感染和严重程度。方法:于2021年12月31日在PubMed、Web of Science、Cochrane、Scopus等在线数据库中检索关键词,检索相关记录。两步筛选;采用标题/摘要和全文筛选,选择符合条件的研究。这些合格的研究进入最后的定性分析。本研究遵循系统评价和荟萃分析首选报告项目(PRISMA)清单,以确保结果的可靠性和有效性。结果:共纳入40项不同血液学恶性肿瘤及COVID-19感染对其影响的研究。研究结果表明,总体而言,血液恶性肿瘤患者的SARS-CoV-2感染患病率和疾病严重程度往往更高,与普通人群相比,患者的发病率和死亡率可能更高。结论:血液学恶性肿瘤患者更易感染COVID-19,病情更严重,死亡率更高。其他合并症的存在也可能使这种情况恶化。建议进一步调查以评估不同亚型血液恶性肿瘤中COVID-19感染的结果。
{"title":"SARS-CoV-2 Infection and Severity in Patients with Hematologic Malignancies: A Systematic Review.","authors":"SeyedAhmad SeyedAlinaghi, Amirali Karimi, Pegah Mirzapour, Roghayeh Salmani, Armin Razi, Hengameh Mojdeganlou, Paniz Mojdeganlou, Mohammad Qodrati, Reyhaneh Jashaninejad, Parinaz Paranjkhoo, Omid Dadras, Besharat Zarezadeh, Amir Masoud Afsahi, Arian Afzalian, Sanaz Varshochi, Esmaeil Mehraeen, Ghazaleh Afsahi","doi":"10.2174/1871526523666230502142256","DOIUrl":"https://doi.org/10.2174/1871526523666230502142256","url":null,"abstract":"<p><strong>Introduction: </strong>Earlier reports described the possibility of higher SARS-CoV-2 infection and severity in patients with hematological malignancies. Given the importance and incidence of these malignancies, we aimed to systematically review SARS-CoV-2 infection and severity in patients with hematologic cancers.</p><p><strong>Methods: </strong>We retrieved the relevant records by searching the keywords in online databases of PubMed, Web of Science, Cochrane, and Scopus on December 31st, 2021. A two-step screening; title/abstract and full-text screening, was employed to select the eligible studies. These eligible studies entered the final qualitative analysis. The study is adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist to ensure the reliability and validity of the results.</p><p><strong>Results: </strong>Forty studies concerning different hematologic malignancies and the effect of COVID-19 infection on them were included in the final analysis. The findings showed that in general, the prevalence of SARS-CoV-2 infection and the severity of the disease are often higher in hematologic malignancies and the patients could experience higher morbidity and mortality compared to general populations.</p><p><strong>Conclusion: </strong>It appeared that individuals with hematologic malignancies are more vulnerable to COVID-19 infection and they experience more severe disease with higher mortality rates. The presence of other comorbidities could also deteriorate this situation. Further investigation is recommended to evaluate the outcome of COVID-19 infection in different subtypes of hematologic malignancies.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 7","pages":"29-38"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10107298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}